Takeda recalls anti-inflammatory Dasen in Japan due to efficacy

22 February 2011

Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), says it has voluntarily recalled Dasen (serrapeptase) 5mg and 10mg tablets, and 1% granules, its anti-inflammatory enzyme preparations sold in Japan, starting on February 21.

In the double-blind studies that have been conducted to compare Dasen with placebo no statistical significant differences were found. Based on the results of these, the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labor and Welfare of Japan held a meeting on January 19, 2011, to consider the drug.

As a result, the Committee pointed out the necessity of conducting additional trials in a manner that reflects current clinical treatment practices, and to prove the efficacy of Dasen. In accordance with the instruction of the MHLW, Takeda has been studying the feasibility of conducting such studies. Takeda believes that the efficacy of Dasen would be confirmed through additional clinical trials with a revised study design, however, it has concluded that it would be difficult to conduct additional studies as requested.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical